中文 English

PlasAimTM Targeted Non-invasive Assay

Detection method

The multiplexed targeted sequencing method used with this assay, compared to PCR and first-generation sequencing methods, is able to simultaneously detect mutations in multiple genes or regions. More genetic information can be obtained from limited amounts patient samples and quickly. 

Test significance

This assay provides guidance for target treatment for common tumors, such as lung cancer, colorectal cancer, breast cancer, and liver cancer. In addition, the test allows the study of the causes of resistance against cancer treatment and to screen for potential drug targets.

Product advantage

1) The cHOPE technology can effectively reduce initial sample volume to as low as 1 mL plasma.  
2) Sequencing depth of at least 10,000X with 0.1% sensitivity.
3) Methylation detection sites are included (only for academic research)




Detection of genes

Tumor genes(52)

  • AKT1
  • CTNNB1
  • GNAS
  • MLH1
  • RET
  • ALK
  • EGFR
  • HNF1A
  • NFE2L2
  • SMAD4
  • APC
  • ERBB2
  • HRAS
  • NOTCH1
  • SMARCB1
  • ATM
  • ERBB3
  • IDH2
  • NRAS
  • SMO
  • BRAF
  • ERBB4
  • JAK1
  • PDGFRA
  • STAT3
  • CBL
  • EZH2
  • JAK2
  • PIK3CA
  • STK11

Applicable to cancer patients

The assay is applicable to common cancers such as lung cancer, breast cancer, colorectal cancer, esophageal cancer, and ovarian cancer when tissue samples cannot be evaluated. It can be applied to:
Cancer patients treated with targeted therapy , in order to identify the best drug.
Cancer patients who failed routine treatment, in order to find the cause of drug resistance or potential target sites.  



Test procedure

*Product is for research use only.